Ignoring Drug Trademarks

68 Pages Posted: 16 Jun 2021

See all articles by Erika Lietzan

Erika Lietzan

University of Missouri School of Law

Date Written: June 10, 2021

Abstract

If you walk into a pharmacy with a prescription for Merck’s ZOCOR, which contains simvastatin, the pharmacist will probably give you a product containing simvastatin made by another company. The pharmacist will dispense a “generic” simvastatin product. State generic substitution laws, passed in the 1970s to help the government save money by switching patients to cheaper generic drugs, either permit or require this substitution. But drug brand names -- such as ZOCOR -- are trademarks. Like other trademarks, they distinguish goods in the market from others, and they signal the source of the goods. These state laws essentially treat the words as something else. As soon as generic drugs are available, state law instructs the pharmacist to read the brand name -- written by the doctor -- as an instruction to dispense a different company's product. This is the opposite of how trademarks are supposed to operate. This Article examines the history of substitution and drug trademarks over the last century and a half, as well as the relationship between the two, against the backdrop of an evolving drug industry, an evolving drug regulatory framework, and improvements in regulatory science. It shows that the generic drug substitution laws are an anomaly in our legal system. Substitution at the pharmacy was illegal, and it still is otherwise illegal. The substitution laws of the 1970s created an exception in pharmacy law and broke with long-standing policy in food and drug law as well as unfair competition law. This Article also shows that the substitution laws were intended to, and did, undermine proprietary (trademark) rights. This was done to achieve savings for payers, after efforts to mandate generic prescribing failed. As the Article points out, much has changed since the 1970s. The regulatory framework has changed, regulatory science has evolved, drug research and development has evolved, the industries have changed, the healthcare finance system is utterly different, the relationship among parties in healthcare delivery has evolved, and so on. The Article therefore concludes by reconsidering (and criticizing) the exception for generic drug substitution, with the benefit of a clear understanding of the relationship between a brand drug and its generic equivalents and a clear understanding of the role for drug trademark after patents have expired. The exception prioritizes short-term cost savings over the dynamic pro-competitive benefits of a properly functioning trademark system. And although the laws are more than 40 years old, this point is important today, because hostility to drug trademarks and devotion to generic substitution laws inform scholarship and policy proposals today.

Keywords: FDA, brand drugs, generic drugs, drug patents, trademark law, brand names, pharmacy law, healthcare finance, history of pharmacy, history of medicine, evergreening, Medicare, Medicaid, food and drug law

Suggested Citation

Lietzan, Erika, Ignoring Drug Trademarks (June 10, 2021). Wake Forest Law Review, Forthcoming, University of Missouri School of Law Legal Studies Research Paper Forthcoming, Available at SSRN: https://ssrn.com/abstract=3863737 or http://dx.doi.org/10.2139/ssrn.3863737

Erika Lietzan (Contact Author)

University of Missouri School of Law ( email )

Missouri Avenue & Conley Avenue
Columbia, MO MO 65211
United States

Do you have a job opening that you would like to promote on SSRN?

Paper statistics

Downloads
82
Abstract Views
628
rank
369,047
PlumX Metrics